Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.37% $8.21
America/New_York / 24 apr 2024 @ 10:28
FUNDAMENTALS | |
---|---|
MarketCap: | 249.89 mill |
EPS: | -0.810 |
P/E: | -10.14 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 30.44 mill |
Avg Daily Volume: | 0.0723 mill |
RATING 2024-04-23 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -10.14 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.72x |
Company: PE -10.14 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$6.57 (-19.96%) $-1.639 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 7.63 - 8.79 ( +/- 7.03%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-03 | Simard John | Buy | 2 470 355 | Convertible Loan Agreement |
2023-06-23 | Waldin Jan-paul | Buy | 25 000 | Director Stock Option |
2023-06-23 | Libby Peter | Buy | 25 000 | Director Stock Option |
2023-06-23 | Macadam Donald H. | Buy | 25 000 | Director Stock Option |
2023-06-23 | Mckenzie W Thorpe | Buy | 25 000 | Director Stock Option |
INSIDER POWER |
---|
97.97 |
Last 100 transactions |
Buy: 4 116 188 | Sell: 11 979 897 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.21 (0.37% ) |
Volume | 0.0030 mill |
Avg. Vol. | 0.0723 mill |
% of Avg. Vol | 4.12 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.